Research Article| Volume 118, ISSUE 5, SUPPLEMENT , 1-3, May 2005


  • David C. Klonoff
    Requests for reprints should be addressed to David C. Klonoff, MD, Diabetes Research Institute, Mills-Peninsula Health Services, 100 South San Mateo Drive, Room 3128, San Mateo, California 94401.
    Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, California, USA
    Search for articles by this author
      Selecting the best pharmacologic therapy for a patient with type 2 diabetes mellitus (DM) requires choosing between various oral agents, insulins, and combinations of oral agents and insulins. As more oral agents and types of insulins have become available over the past decade, the number of options for single-drug and multidrug therapy has increased progressively. The decision process must factor in the patient’s disease duration, current degree of control, responses to previous pharmacologic regimens, and likelihood of adherence to therapy. The authors of the articles in this supplement to The American Journal of Medicine provide insight into developing a rational approach to selecting and combining oral agents, transitioning from oral therapy to insulin therapy, intensifying insulin therapy, and improving adherence to pharmacologic therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chan A.W.
        • Krleza-Jeric K.
        • Schmid I.
        • Altman D.G.
        Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.
        CMAJ. 2004; 171: 735-740
        • Bloomgarden Z.T.
        Gut-derived incretin hormones and new therapeutic approaches.
        Diabetes Care. 2004; 27: 2554-2559
      1. Klonoff DC. Continuous glucose monitoring: roadmap to 21st century diabetes therapy. Diabetes Care. In press.

        • Hermansen K.
        Waiting to inhale.
        Curr Diab Rep. 2004; 4: 335-341